Peptide guide

Sermorelin: what it is and what the research actually shows

A 29 amino acid fragment of natural growth hormone releasing hormone that was FDA approved for childhood growth hormone deficiency, pulled from the market by its maker in 2009, and is now sold mainly through compounding pharmacies and research chemical sites.

Byline: Mark Sommers, editor. Sources checked 08-26-2026. Every claim below links to its PubMed record or FDA page.

Quick facts

What is in it
  • One synthetic peptide, a short lab made piece of natural human growth hormone releasing hormone, built to signal the pituitary gland to release its own growth hormone.

One molecule, not a blend. In practice it is very commonly sold mixed with other peptides such as CJC-1295, ipamorelin, or GHRP-6 in compounded growth hormone stacks, and none of the studies below tested those combinations.

Studied for
Trials from the 1990s mostly measured height velocity, bone age, and blood levels of growth hormone and IGF-1 in children with growth hormone deficiency, in some cases comparing sermorelin head to head against growth hormone itself. A separate, smaller set of studies from the early 1990s measured growth hormone and IGF-1 levels, body composition, and general well being in healthy older adults. A single injected dose was also studied as a way to help tell whether a child's growth hormone deficiency comes from the pituitary gland itself or from a signal that never reaches it.
Human evidence, part by part
SermorelinLimited31 human studies found
Approved by the FDA?
Not approved for sale in the United States today. Sermorelin held two FDA approvals, one in 1990 for a diagnostic test and one in 1997 for treating growth hormone deficiency in children, and its maker discontinued both products in 2008 and 2009. FDA later determined the withdrawal was not for reasons of safety or effectiveness, but that finding did not put sermorelin back on pharmacy shelves. See where it stands.

Benefits

  • Evidence Raised height velocity from about 4 to 8 cm per year at 6 months, in a 110-child trial. PMID 8772599
  • Evidence Raised growth hormone and IGF-1 in older men to levels matching younger men after two weeks, in 19 people. PMID 1379256
  • Evidence Increased lean body mass and libido in men, though not women, after four months in a 19-person trial. PMID 9141536
  • Evidence Raised height velocity in nine children with radiation-induced growth hormone deficiency over one year. PMID 9231053
  • Suggested Discussed as a milder, more natural alternative to injected growth hormone, per online clinician commentary.
  • Suggested Promoted for general anti-aging and wellness use, resting mainly on two small 1990s studies.
  • Suggested Discussed for muscle and recovery goals, though clinicians note wellness-clinic doses often run far below research doses.

Evidence items link to the study behind them. Suggested items are claims in circulation, not results.

Reported side effects

  • The most common reported issues were facial flushing and injection-site pain, per a 1999 drug review. PMID 18031173
  • Fasting glucose and insulin rose during a year of treatment in an 18-person short-stature trial. PMID 7955460
  • A transient rise in blood fats occurred in a small trial in older adults, resolving by its end. PMID 9141536
  • A 2026 case report raised a neck bone spur as a possible issue after decades of unsupervised combined drug use. PMID 42465868
  • Its two FDA approvals were withdrawn from the market in 2009, though not for safety or effectiveness.

Safety, before anything else

Sermorelin is not an approved medicine in the United States today. It held two FDA approvals, in 1990 and 1997, before its maker discontinued it from the market in 2008 and 2009. FDA later determined that withdrawal was not for reasons of safety or effectiveness, but that finding did not put sermorelin back on pharmacy shelves. Almost everything sold as sermorelin today comes from compounding pharmacies, telehealth clinics, and research chemical sites, outside the FDA-reviewed supply chain that once existed. Here is every safety signal in the published record, before you read anything about what it might do.

Sermorelin

  • In the year-long pediatric trial of 110 children, no adverse changes in general blood chemistry or hormone levels were reported, fasting glucose did not rise, and the treatment was described as well tolerated overall. PMID 8772599
  • Across the studies summarized in this 1999 drug review, the most commonly reported side effects were transient facial flushing and pain at the injection site. Single intravenous doses and repeated daily injections were both generally well tolerated. PMID 18031173
  • The one adverse effect noted in this small trial in older adults was a transient rise in blood fats, which resolved by the end of the study. PMID 9141536
  • Fasting blood glucose and insulin both rose during a year of treatment in this short stature trial, alongside the expected rise in IGF-1, a metabolic pattern worth watching in anyone using a growth hormone axis stimulator for a long stretch of time. PMID 7955460
  • A single 2026 case report raises the possibility that decades of chronic, unsupervised stimulation of the growth hormone axis, including a period of sermorelin combined with GHRP-6, may have contributed to abnormal bone spur growth in the neck of one patient. This is one confounded case involving multiple drugs at once, not an established risk of sermorelin alone. PMID 42465868
  • FDA's list of compounded peptides with identified significant safety risks names CJC-1295, ipamorelin, and GHRP-2, peptides commonly sold alongside or blended with sermorelin. Sermorelin itself is not on that list, but that reflects what FDA has formally reviewed and flagged, not proof that the stacked products people actually buy are safe.

We do not publish amounts or schedules of our own, on any page. The clinician commentary lower on this page quotes amounts that named clinicians state on camera, labeled and linked to the source video. Those are their words, not our guidance. Why we draw that line.

How to read the grades

Each study gets a tag. Cells in a dish means it never touched a living animal. Animals means mice or rats, usually. Small human study means a handful of people with no comparison group. Human trial means people were randomly split into treated and untreated groups, which is the only kind that can show an effect is real. Review and Systematic review sum up other studies. The full rule is on How we check.

Sermorelin

Sermorelin is a lab made, 29 amino acid piece of the front end of human growth hormone releasing hormone, the natural signal that tells the pituitary gland to release growth hormone in pulses. Because it acts on the gland's own release machinery rather than replacing growth hormone directly, the theory is that it preserves the body's normal pulsing pattern and built in shutoff signals in a way that injecting growth hormone itself does not. It was studied and approved for two narrow uses: a single injection to help work out whether a child's growth hormone deficiency comes from the pituitary gland itself or from a signal that never reaches it, and a daily injection to treat that deficiency once diagnosed. A separate, much smaller body of research from the early 1990s tested it in healthy older adults, on the idea that restoring growth hormone pulses lost with age might reverse some effects of aging. Those aging studies measured hormone levels and a few markers of body composition and well being, not the health outcomes people actually care about, like strength, falls, or independence.

Human evidence: Limited. 31 human studies found in our search.

What has been studied

Who or what was studiedWhat was found, and the catchSource
Small human study
n = 110 people
In a multicenter, open label study of previously untreated prepubertal children with growth hormone deficiency, once daily injections of the peptide over one year raised mean height velocity from about 4.1 cm per year at baseline to about 8.0 cm per year at 6 months and 7.2 cm per year at 12 months, and about 74% of children were rated as responding well at 6 months.
Limit: There was no placebo or growth hormone comparison group, so the growth seen here could not be checked against either doing nothing or the standard treatment. Only 86 of the 110 enrolled children had usable efficacy data. Everyone involved knew what treatment was being given, and the study was organized and funded through the manufacturer's own international study group.
Thorner 1996
PMID 8772599
Small human study
n = 7 people
In seven children with growth hormone deficiency of hypothalamic origin, continuous injections of the peptide for at least six months failed to improve the growth rate in five of the seven children; switching those same children to growth hormone itself then improved growth in all of them.
Limit: Seven children from one center, with no randomization or blinding. This is one of the more discouraging results in the sermorelin literature: the peptide did not work for most of these particular patients, while growth hormone did, in the same children.
Butenandt 1989
PMID 2537727
Human trial
n = 43 people
In 43 children with hypothalamic growth hormone deficiency randomly assigned to a lower dose of the peptide, a higher dose, or growth hormone itself for six months, height velocity was lowest in the lower dose group and roughly matched between the higher dose group and the growth hormone group, though a gain in height relative to bone age only showed up in the growth hormone group.
Limit: This is a randomized, multi arm comparison, which is rare in this literature, but each group held only 12 to 16 children, it ran just six months, and it was published as a conference supplement report rather than a full peer reviewed paper with complete statistics.
Neyzi 1993
PMID 8329826
Small human study
n = 18 people
In 18 short children who were not growth hormone deficient, a year of twice daily injections raised height velocity from about 4.8 to 7.2 cm per year, then growth slowed back toward pretreatment levels within six months of stopping, while fasting glucose, insulin, and IGF-1 all rose during treatment.
Limit: This was short stature without a diagnosed hormone deficiency, not the approved use of treating growth hormone deficiency, so it does not speak to sermorelin's core indication. There was no placebo arm, only 18 patients at one center, and the growth gain reversed after treatment stopped, raising the question of whether it produces lasting height or a temporary growth spurt.
Kirk 1994
PMID 7955460
Small human study
n = 9 people
In nine children with radiation-induced growth hormone deficiency after treatment for a brain tumor or as leukemia prevention, a year of the peptide raised height velocity from about 3.3 to 6.0 cm per year, though switching those children to growth hormone itself for the following year raised velocity further, to about 7.5 cm per year.
Limit: Nine patients across multiple centers is a very small base for this specific subgroup. There was no control group and no blinding, and the authors state plainly that the peptide's own effect was smaller than growth hormone's in the same children.
Ogilvy-Stuart 1997
PMID 9231053
Review
This drug evaluation review summarized the sermorelin dataset available at the time: an intravenous dose was described as a fairly specific test for growth hormone deficiency, producing fewer false positives than some older provocative tests, though a normal response could not rule out a hypothalamic problem on its own. Daily injected sermorelin produced sustained height velocity gains over 12 months, and in a small number of children followed longer, over 36 months, but growth on sermorelin was smaller than growth on growth hormone itself in head to head comparisons.
Limit: This is a manufacturer-adjacent drug class review from Adis International, not new data, built largely from the same small open label and comparative studies summarized elsewhere in this file. It predates any published final adult height data and any large randomized trial.
Prakash 1999
PMID 18031173
Human trial
n = 19 people
In a crossover study comparing 10 healthy older men with 9 younger men, two weeks of twice daily injections raised 24 hour growth hormone release and IGF-1 in the older men to levels no longer statistically different from the younger men's baseline, an effect that only reached significance at the higher of two doses tested.
Limit: Two weeks is a short exposure to base a claim about reversing an age-related hormone decline on, the young and old groups were tiny, and every outcome measured was a blood hormone level, not anything the participants could feel or a doctor could measure as a real world change in strength, body composition, or function.
Corpas 1992
PMID 1379256
Human trial
n = 19 people
In 19 healthy adults aged 55 to 71 given four weeks of placebo followed by 16 weeks of the peptide, nightly injections raised IGF-1 into the normal range for younger adults within two weeks. After four months, men, but not women, showed more lean body mass, better insulin sensitivity, improved general well being, and higher libido, while skin thickness increased in both sexes.
Limit: Only 19 people total, single blind rather than double blind, and the benefits split sharply by sex, with women showing almost none of the functional gains seen in men, a pattern the authors could not explain. This one small, single-center trial is a primary basis for anti-aging marketing claims made about sermorelin today.
Khorram 1997
PMID 9141536
Small human study
n = 1 people
A 62 year old man with about 20 years of largely unsupervised use of growth hormone and growth hormone releasing peptides, including a period of sermorelin combined with GHRP-6 plus ongoing nightly growth hormone, was found to have a bone spur at the front of his neck pressing on his esophagus and causing occasional trouble swallowing large bites of food. The authors raise chronic stimulation of the growth hormone axis as a possible contributor.
Limit: One patient, with decades of mixed, self-directed use of at least three different growth-axis drugs at once and no medical supervision, so nothing here can be pinned on sermorelin specifically. This is a hypothesis-generating case report, not evidence of a typical outcome.
Perez 2026
PMID 42465868

Safety signals in the studies

  • In the year-long pediatric trial of 110 children, no adverse changes in general blood chemistry or hormone levels were reported, fasting glucose did not rise, and the treatment was described as well tolerated overall. PMID 8772599
  • Across the studies summarized in this 1999 drug review, the most commonly reported side effects were transient facial flushing and pain at the injection site. Single intravenous doses and repeated daily injections were both generally well tolerated. PMID 18031173
  • The one adverse effect noted in this small trial in older adults was a transient rise in blood fats, which resolved by the end of the study. PMID 9141536
  • Fasting blood glucose and insulin both rose during a year of treatment in this short stature trial, alongside the expected rise in IGF-1, a metabolic pattern worth watching in anyone using a growth hormone axis stimulator for a long stretch of time. PMID 7955460
  • A single 2026 case report raises the possibility that decades of chronic, unsupervised stimulation of the growth hormone axis, including a period of sermorelin combined with GHRP-6, may have contributed to abnormal bone spur growth in the neck of one patient. This is one confounded case involving multiple drugs at once, not an established risk of sermorelin alone. PMID 42465868
  • FDA's list of compounded peptides with identified significant safety risks names CJC-1295, ipamorelin, and GHRP-2, peptides commonly sold alongside or blended with sermorelin. Sermorelin itself is not on that list, but that reflects what FDA has formally reviewed and flagged, not proof that the stacked products people actually buy are safe.

Where it stands with regulators

  • FDA notice, Federal Register 78 FR 14095, published March 4, 2013, checked 08-26-2026. FDA states that GEREF (sermorelin acetate) injection, in both its vial strengths and its ampule strength, was not withdrawn from sale for reasons of safety or effectiveness. Both products stay on the Orange Book's Discontinued Drug Product List, which under FDA rules still permits a generic (ANDA) to be approved against them. Source
  • FDA notice, Federal Register 74 FR 23407, published May 19, 2009, checked 08-26-2026. FDA withdrew approval of NDA 19-863 and NDA 20-443, the two sermorelin (Geref) applications, effective June 18, 2009, after EMD Serono notified FDA in writing that it had stopped marketing both products and requested the withdrawal. Source
  • Drugs@FDA query run 08-26-2026, checked 08-26-2026. Both sermorelin applications, NDA 019863 (approved 1990, diagnostic use) and NDA 020443 (approved 1997, treatment of pediatric growth hormone deficiency), currently show marketing_status 'Discontinued', each carrying the note that FDA determined the product was not discontinued or withdrawn for safety or effectiveness reasons. Source
  • FDA 503A bulk drug substances page, content current as of 05/14/2026, checked 08-26-2026. Sermorelin does not appear on this list, so it has not been formally added, through FDA rulemaking, as a bulk substance approved for 503A pharmacy compounding. Source
  • FDA list of bulk drug substances that may present significant safety risks in compounding, content current as of 04/22/2026, checked 08-26-2026. This list names CJC-1295, ipamorelin, and GHRP-2, peptides often sold alongside or blended with sermorelin, but sermorelin itself is not on it. Source

What is missing

Nearly the entire evidence base is from the 1990s, in small groups, often single digit to low double digit sample sizes per arm, with no modern randomized trial repeating any of it. There is no published final adult height data from the pediatric growth hormone deficiency trials, only height velocity over roughly a year. The aging data rests on two small studies from the early 1990s, two weeks and sixteen weeks long, measuring blood hormone levels rather than outcomes people would notice, and the one trial that did measure function found benefits in men but not in women, a split nobody has explained or retested. There is no evidence here on what today's compounded sermorelin products actually contain or whether they match the formulation used in these old trials.

Clinician commentary (YouTube)

This is commentary, not evidence. 4 clinicians with large audiences discuss this on camera. Each video below is summarized in our words and linked so you can watch the source yourself. Any amounts mentioned are what the named clinician says on camera, not PeptideGauge guidance. The graded studies above remain the record of what is known. How this layer works.

Dr. Alex Tatem

In “Sermorelin: The “Safer HGH” Has One Huge Problem”, Dr. Alex Tatem discusses Sermorelin. What he says, in short:

  • He explains sermorelin is just the first 29 amino acids of growth hormone releasing hormone, so it asks the pituitary to release its own growth hormone rather than replacing it, which caps how much GH it can produce and means it does nothing if the pituitary itself is damaged.
  • He traces its history: GHRH was sequenced in 1982 from acromegaly tumor patients, sermorelin was approved as Geref in December 1990 and got a pediatric growth-deficiency indication in 1997 dosed at 30 micrograms per kilo nightly, about 2.1 mg for a 70 kg adult, and it was withdrawn from sale in 2009 for commercial reasons, which the FDA confirmed in 2013 was not a safety or efficacy issue, which is why it can still be compounded today.
  • Ranking the evidence, he says sleep is the strongest claim, with real EEG data showing close to a tenfold increase in slow-wave sleep and lower nocturnal cortisol; skin thickness rose about 7% in the 1990 trial but the result was not statistically significant; hair and nails have no trials at all, just plausibility; and visceral fat reduction is proven for its cousin tesamorelin, not for sermorelin itself.
  • On muscle, he says real growth hormone studies show it builds collagen, tendon and water weight rather than actual muscle protein, and that GHRH doses shown to change body composition were 4 mg twice daily, while typical clinic sermorelin doses of 100 to 300 micrograms nightly are roughly a tenth of even the lower dose that failed to work in a trial, so most people feeling nothing are simply underdosed for that outcome.
  • He lists side effects as mild, injection site pain or redness in about one in six people and transient flushing, says it does not raise cortisol or blunt blood sugar the way real growth hormone can, and debunks the idea that it spikes cortisol, attributing that effect instead to ghrelin-receptor drugs like GHRP-2, GHRP-6 and hexarelin.
  • His bottom line is that he does not consider it a muscle-building drug and says the sleep benefit is the one claim with real human trial support, so if used it should be dosed at levels that actually appeared in studies, monitored with IGF-1 testing, and paired with resistance training and protein intake for anyone chasing muscle.

Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Alex Tatem’s, not ours.

In “Truth About Popular Peptides Tier List (What Works, What’s Overhyped) | Pt. 3”, Dr. Alex Tatem discusses Sermorelin. What he says, in short:

  • He introduces it, transcribed here as Samorlin or Samorland, as an original growth hormone secretagogue that was once pursued commercially, then abandoned into what he calls an orphan drug category that lets most major compounding pharmacies make it.
  • He describes it as the end-terminal fragment of growth hormone releasing hormone, meaning it stimulates a small, natural rise in growth hormone and IGF-1, calling the effect very subtle.
  • He ranks its benefits as the classic mild growth hormone effects, better sleep, better skin, and maybe a little fat loss, adding that even the fat loss claim is stretching it.
  • He stresses it is safe and available through legitimate high-quality compounding pharmacies rather than gray-market sourcing, typically dosed as a small nightly subcutaneous injection.
  • He grades it favorably as a lifestyle and longevity compound for sleep and skin (the ASR renders the exact letter grade unclear, though the context suggests a high tier), while explicitly saying it does not earn that same ranking for muscle building.

Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Alex Tatem’s, not ours.

1 more video where Dr. Alex Tatem covers Sermorelin

In “Every Popular Peptide Ranked | GLP-1, Growth Hormone, HCG, NAD+, IGF-1, Peptide Tier List”, Dr. Alex Tatem discusses Sermorelin. What he says, in short:

  • He explains Sermorelin is the N-terminal fragment of growth hormone releasing hormone, mildly boosting the body's own growth hormone and IGF-1, and sits in a legal orphan-drug loophole that makes it widely available through compounding pharmacies.
  • He says its benefits are small but real: modestly better sleep and skin, and a little fat loss, not hypertrophy.
  • He gives it an A tier ranking specifically as a lifestyle and longevity compound, not for muscle building.

Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Alex Tatem’s, not ours.

Dr. Ashley Froese

In “Doctor Explains 10 Most Fascinating Peptides”, Dr. Ashley Froese discusses Sermorelin. What she says, in short:

  • She calls sermorelin the "OG of the growth hormone boosting peptides" and opens her extended peptide list with it.
  • She says it is made of the first 29 amino acids of growth hormone releasing hormone, which prompts the pituitary to release more growth hormone.
  • She says the most popular reasons people use it on their own bodies are increased muscle mass, strength gains, fat loss, and improved sleep.
  • She warns that growth hormone does not discriminate, so raising it by any means, including sermorelin, could in theory grow any tissue, including cancer cells.

Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Ashley Froese’s, not ours.

In “Dr Amazed - Tesamorelin DECIMATES Visceral Fat and MORE”, Dr. Ashley Froese discusses Sermorelin. What she says, in short:

  • She groups sermorelin with tesamorelin and CJC-1295 as growth hormone releasing hormone mimetic peptides, but says sermorelin and CJC-1295 are only short fragments of GHRH that get broken down quickly by the enzyme DPP-4.
  • She compares them to "kids who crash your party" that don't stick around, versus tesamorelin, which she calls the "birthday boy" that stays in the body much longer.

Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Ashley Froese’s, not ours.

2 more videos where Dr. Ashley Froese covers Sermorelin

In “Learn Peptides So Fast it's UNREAL”, Dr. Ashley Froese discusses Sermorelin. What she says, in short:

  • She places sermorelin in her recovery bucket as a growth hormone releasing hormone analog.
  • She says it stimulates the pituitary to release growth hormone in a natural pulsatile pattern, unlike synthetic growth hormone, which floods the system.
  • She describes this pulsatile release as how the body is designed to use growth hormone, framing sermorelin as reminding the pituitary to do its job.

Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Ashley Froese’s, not ours.

In “Muscle Builder or More? Dr Reviews Ipamorelin”, Dr. Ashley Froese discusses Sermorelin. What she says, in short:

  • She describes sermorelin as one of the GHRH mimicking peptides, alongside CJC-1295 and tesamorelin, that stimulate the pituitary's scheduled growth hormone system.
  • She says GHRH peptides like sermorelin can lose effectiveness over time because repeated daily stimulation can down regulate their receptors, unlike ipamorelin.
  • She mentions some people use sermorelin at bedtime to support the body's natural overnight growth hormone rhythm, while reserving ipamorelin for daytime use around training.
  • She says she has personally seen severe allergic reactions, close to anaphylaxis, with sermorelin as well as CJC-1295 and tesamorelin, though she says this is not common.

Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Ashley Froese’s, not ours.

Dr. Craig Koniver

Dr. Craig Koniver does not run a channel of his own. Each video below is an interview published by the show that recorded it.

In “Peptide & Hormone Therapies for Health, Performance & Longevity | Dr. Craig Koniver” on Andrew Huberman, Dr. Craig Koniver discusses Sermorelin. What he says, in short:

  • He groups sermorelin with tesamorelin as acting on the growth hormone releasing hormone side, higher up the chain than ipamorelin, hexarelin or GHRP-6.
  • He says that with sermorelin and tesamorelin you do not necessarily need to add anything else, whereas with ipamorelin, hexarelin or GHRP-6 his clinic classically added CJC-1295.
  • He says CJC-1295 can now largely be set aside because the FDA removed it, which he frames as one acronym taking out another.
  • He says he thinks of these growth hormone releasing peptides as having different flavors and that individual responses vary, which is why he thinks people should work with an experienced physician.
  • He agrees with Huberman that one person can react badly to sermorelin while other people love it and see none of the same issues, and does not dispute the account.
  • He describes a bedtime stack that can combine sermorelin or tesamorelin with ipamorelin, dosed five days on and two days off.

I think of these peptides as having flavors particularly the growth hormone releasing peptides

Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Craig Koniver’s, not ours. Quoted lines are taken from the automatic captions on the video, so the wording can differ slightly from the audio.

Dr. Jones, DC

In “Dr. Explains Why CJC/IPA is KING of Growth Hormone Peptides”, Dr. Jones, DC discusses Sermorelin. What he says, in short:

  • He calls sermorelin the old-school option and the native GHRH, the same signaling molecule the body already makes.
  • He says its problem is that it is short-acting with a half-life measured in minutes, so it clears fast and needs frequent dosing just to keep levels up.
  • He says that even with frequent dosing you do not get sustained exposure from sermorelin.
  • He contrasts it with CJC-1295, which he says is albumin-bound and stays in the system for days rather than minutes, giving sustained IGF-1 elevation without multiple daily injections.
  • He concludes that sermorelin had its moment but that the moment is past, ranking it below CJC with ipamorelin and below tesamorelin in his hierarchy.

Sermorelin had its moment, but that moment is past.

It's short-acting. Its half-life measures in minutes.

Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Jones, DC’s, not ours. Quoted lines are taken from the automatic captions on the video, so the wording can differ slightly from the audio.

In “Doctor Reveals The Best Peptide Stack For Lean Muscle Growth for 2026”, Dr. Jones, DC discusses Sermorelin. What he says, in short:

  • He presents sermorelin as the third option in his growth hormone stack and calls it a tried-and-true peptide.
  • He says it is not as strong as CJC-1295 with ipamorelin, but states that it is also FDA-approved.
  • He says that if sermorelin were all a person had access to he would take it bar none, while steering people ideally toward CJC with ipamorelin or tesamorelin.
  • He describes its benefits as broadly similar to the other secretagogues, listing fat loss support, muscle building support, enhanced recovery, reduced inflammation and general anti-aging effects from raising growth hormone release.
  • He ties the benefit back to sleep, saying growth hormone has its biggest release during sleep so anything supporting that nighttime release helps recovery and tissue repair.

not as strong as CJC ipamorelin, but it's also FDA-approved. And if this is all you had access to, I would take this, bar none.

Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Jones, DC’s, not ours. Quoted lines are taken from the automatic captions on the video, so the wording can differ slightly from the audio.

2 more videos where Dr. Jones, DC covers Sermorelin

In “The ULTIMATE Peptide Stack For Fat Loss & Metabolic Flexibility! | Dr. Jones DC”, Dr. Jones, DC discusses Sermorelin. What he says, in short:

  • He says sermorelin is FDA-approved for growth hormone deficiency in children and adults.
  • He states as a dosing pattern that sermorelin is usually run 5 days on and 2 days off, in the morning and definitely fasted.
  • He says somewhere closer to a couple hundred micrograms a day is a solid dose for sermorelin.
  • He ranks it below CJC-1295 with ipamorelin, saying that combination is definitely better if you can get it but that sermorelin would work as well.
  • He groups sermorelin with the other growth hormone secretagogues as tools for improving metabolic flexibility alongside a GLP-1, while saying he still prefers AOD-9604 for that specific job.

Sermorelin is actually FDA-approved for growth hormone deficiency in children and adults.

somewhere closer to a couple hundred micrograms a day is a solid dose for Sermorelin

Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Jones, DC’s, not ours. Quoted lines are taken from the automatic captions on the video, so the wording can differ slightly from the audio.

In “Doctor Reveals The Best Peptide Stack For Massive Muscle Growth in 2026”, Dr. Jones, DC discusses Sermorelin. What he says, in short:

  • He calls sermorelin the tried-and-true growth hormone option and the mildest of the three he compares.
  • He says it has the shortest half-life of the group and the most natural rhythm, which he gives as the reason he still includes it.
  • He emphasizes sleep quality as sermorelin's practical benefit, arguing that sleep is when the body actually builds, while noting that all the growth hormone peptides do this too.
  • He says it is historically FDA approved, which he says gives him confidence in the safety profile.
  • He positions it as the conservative choice that can still be used strategically and effectively, behind CJC with ipamorelin and tesamorelin.

It is the mildest of the group, shortest half-life,

Link checked 08-26-2026. The summary is our paraphrase; the claims are Dr. Jones, DC’s, not ours. Quoted lines are taken from the automatic captions on the video, so the wording can differ slightly from the audio.

Common questions

Can I legally buy sermorelin?

It sits in a gray zone. Sermorelin is not an approved drug today, but unlike a never-approved molecule, its withdrawal was determined by FDA not to be for safety or effectiveness reasons, which is the legal opening compounding pharmacies rely on to source and sell it. It has not gone through FDA's formal 503A rulemaking process that lists substances cleared for compounding, and it is also not on FDA's separate list of compounded peptides flagged for significant safety risk, unlike some peptides it is commonly sold with. In practice it is widely sold by compounding pharmacies, telehealth clinics, and research chemical websites, generally without the kind of medical work-up its original approved use required.

Was sermorelin ever an actual approved medicine?

Yes, twice. FDA approved a diagnostic injection in 1990 and a treatment injection for childhood growth hormone deficiency in 1997, both sold under the brand name Geref by EMD Serono. The company discontinued both products in 2008 and 2009, and FDA formally withdrew the approvals in 2009. In 2013, after a citizen petition asked FDA to check, the agency determined the withdrawal was not for reasons of safety or effectiveness.

Why did the manufacturer stop selling it, if not for safety?

The public record does not say. EMD Serono's letters to FDA simply stated the products were being discontinued and asked that the approvals be withdrawn; no reason is given in the Federal Register notices. Business reasons, such as low sales against growth hormone itself, are the common assumption, but that is an assumption, not something documented in the public filings checked here.

Does sermorelin actually make you taller, more muscular, or younger?

Raising a growth hormone or IGF-1 level on a blood test is not the same thing as a benefit a person feels. In children with diagnosed growth hormone deficiency, sermorelin did increase height velocity in several studies, though usually by less than growth hormone itself achieved head to head, and in at least one small study it did not work for most of the children given it. In healthy older adults, the two main trials found on this page ran two weeks and sixteen weeks and mostly measured hormone levels; the one that tracked function found gains in men but not women, in a single small trial nobody has repeated.

How is sermorelin different from peptides like CJC-1295 or ipamorelin that it's often sold with?

Sermorelin is the actual 29 amino acid fragment of natural human growth hormone releasing hormone, one of the oldest and most studied compounds in this drug class, with a real, if old and discontinued, FDA approval behind it. CJC-1295 and ipamorelin are different, more recently engineered peptides built to last longer in the body or act through a different receptor; neither has ever been FDA approved, and FDA has specifically flagged both, along with GHRP-2, as compounded substances that may carry significant safety risks. Sermorelin is not on that flagged list, but products sold as sermorelin are frequently blended with these other peptides, and none of the sermorelin studies here tested those combinations.

What are the known side effects?

In the studies reviewed here, the most commonly reported issues were mild and local: facial flushing and pain at the injection site. One small trial in older adults reported a transient rise in blood fats. One pediatric trial saw fasting glucose and insulin rise during treatment, alongside the expected IGF-1 increase. A single 2026 case report raised bone spur growth in the neck as a possible long-term issue after decades of combined, unsupervised growth-hormone-axis drug use, though that case involved several drugs at once and cannot be pinned on sermorelin alone.

What would make this evidence base stronger?

A modern, adequately sized randomized trial of sermorelin specifically, rather than 1990s studies with single or double digit sample sizes in some arms. Published final adult height outcomes from the pediatric growth hormone deficiency trials, which mostly stopped at one year of height velocity. A repeat of the aging trials with a real functional outcome, like strength or falls, instead of blood hormone levels, and an explanation for why the one functional aging trial found benefits in men but not women. And some accounting for what compounded sermorelin products actually contain today, since the tightly controlled formulation used in the 1990s trials is not the same regulatory product being sold now.

Sources

  1. Butenandt (1989). PMID 2537727
  2. Corpas (1992). PMID 1379256
  3. Khorram (1997). PMID 9141536
  4. Kirk (1994). PMID 7955460
  5. Neyzi (1993). PMID 8329826
  6. Ogilvy-Stuart (1997). PMID 9231053
  7. Perez (2026). PMID 42465868
  8. Prakash (1999). PMID 18031173
  9. Thorner (1996). PMID 8772599

Sermorelin was FDA approved under the brand name Geref, as NDA 19-863 in 1990 for diagnostic use and NDA 20-443 in 1997 for treating pediatric growth hormone deficiency, then discontinued from the market by EMD Serono in 2008 and 2009. In 2013 FDA determined that withdrawal was not for reasons of safety or effectiveness. Sermorelin does not appear on FDA's current list of bulk drug substances approved for 503A compounding, and it is not on FDA's list of compounded peptides identified as carrying significant safety risks, unlike companion peptides CJC-1295, ipamorelin, and GHRP-2, which are on that list. Checked 08-26-2026.

Want these studies next to every other one on the site?

Open the evidence table

Mixing a vial? Do the math with the calculator.

Open the calculator